Asta Bio
- | Biotech or pharma, therapeutic R&D
At Asta Bio, we’re pioneering a unique approach by harnessing the superior properties of alpha emitter 211-Astatine in combination with our proprietary multispecific Radiobodies™ that provide better targeting to tumor cells while leaving the body quickly without harming normal cells.
Our lead molecule, ASTA-101 is a bispecific 211-Astatine Radiobody that is in preclinical development for multiple solid tumors.
Our goal is to develop radiotherapies for breast cancer, NSCLC, head and neck cancer, ovarian cancer, bladder cancer, and more.
Asta Bio was founded in 2024 with initial investment from IndieBio/SOSV, the investors round. We’ve since begun our operations and research in collaboration with Duke University.
Address
BostonMassachusetts
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}